Alys Pharmaceuticals chair Francesco De Rubertis (L) and COO Thibaud Portal
Centessa 2.0 with a twist: Medicxi combines six immuno-derm startups with $100M
European biotech investor Medicxi is bringing six startups under one roof to form an immuno-dermatology drugmaker with 14 pipeline projects in a move reminiscent of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.